I-Mab, a biotech company, focuses on the development of immuno-oncology agents for the treatment of cancer in the United States. The company is developing givastomig, a bispecific antibody, which is in Phase 1b clinical trial for the treatment of gastric cancer; uliledlimab, a CD73 neutralizing antibody; and ragistomig, a bispecific antibody, which is in phase 1 clinical trial for the treatment of solid tumors. It has a strategic licensing agreement with Ferring International Center SA to research, develop, make, have made, import, use, sell, and offer to sell FE301, an interleukin-6 inhibitor. The company also has collaborations with Bristol Myers Squibb for the development of givastomig; ABL Bio, Inc. for the development of givastomig and ragistomig; and TJ Bio for the development of uliledlimab. I-Mab was founded in 2014 and is headquartered in Rockville, Maryland.
Metrics to compare | IMAB | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipIMABPeersSector | |
---|---|---|---|---|
P/E Ratio | −14.0x | −3.5x | −0.6x | |
PEG Ratio | −0.21 | −0.10 | 0.00 | |
Price/Book | 2.6x | 2.5x | 2.6x | |
Price / LTM Sales | - | 89.4x | 3.3x | |
Upside (Analyst Target) | 33.3% | 212.4% | 38.7% | |
Fair Value Upside | Unlock | −6.3% | 5.1% | Unlock |